| Year |
Citation |
Score |
| 2020 |
Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M. Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). Journal of Cancer Research and Clinical Oncology. PMID 32886212 DOI: 10.1007/S00432-020-03327-2 |
0.351 |
|
| 2020 |
Albers P, Wiegel T, Schmidberger H, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Meisner C, Wellek S, Grozinger K, Renner P, Burmester M, Schneider F, Stöckle M. Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial. World Journal of Urology. PMID 32189088 DOI: 10.1007/S00345-020-03154-7 |
0.362 |
|
| 2020 |
Brandt MPJK, Ruf CG, Dieckmann KP, Syring I, Ruckes C, Hiester A, Albers P, Christian B, Heidenreich A, Haferkamp A, Zengerling F, Paffenholz P. Multicenter analysis of serum tumor markers, treatment patterns, and relapse in patients with testicular cancer in clinical stage IS. Journal of Clinical Oncology. 38: 5052-5052. DOI: 10.1200/Jco.2020.38.15_Suppl.5052 |
0.306 |
|
| 2020 |
Bravi C, Fossati N, Motterle G, Karnes J, Schmautz M, Heidenreich A, Kretschmer A, Buchner A, Stief C, Devos G, Joniau S, Poppel HV, Osmonov D, Juenemann K, Grubmüller B, ... ... Albers P, et al. Mp79-02 Performance Characteristics Of Pet/Ct Scan In Men Treated With Salvage Lymph Node Dissection For Recurrent Prostate Cancer: A Per Patient Analysis With Pathological Confirmation According To Each Area Of Dissection The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000971.02 |
0.34 |
|
| 2020 |
Nini A, Boschheigen M, Hiester A, Winter C, Antoch G, Schimmöller L, Albers P. Mp76-04 Preoperative Clinical And Radiographic Predictors Of Major Vascular Reconstructions In Patients With Testicular Cancer Undergoing Postchemotherapy Residual Tumor Resection (Pc-Rplnd) The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000962.04 |
0.31 |
|
| 2020 |
Herkommer K, Meissner VH, Hollerer M, Kron M, Schiele S, Albers P, Arsov C, Kuczyk M, Imkamp F, Hohenfellner M, Schütz V, Gschwend JE. Mp75-05 Effect Of Sexual Behavior On Prostate-Specific Antigen Levels In Middle-Aged Men Screened For Prostate Cancer: Results From The Probase Trial The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000961.05 |
0.307 |
|
| 2019 |
Ullrich T, Quentin M, Arsov C, Laqua N, Abrar D, Hiester A, Albers P, Antoch G, Schimmöller L. Value of Dynamic Contrast-Enhanced (DCE) MR Imaging in Peripheral Lesions in PI-RADS-4 Patients. Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin. PMID 31622990 DOI: 10.1055/A-1020-4026 |
0.302 |
|
| 2019 |
Sawicki LM, Kirchner J, Buddensieck C, Antke C, Ullrich T, Schimmöller L, Boos J, Schleich C, Schaarschmidt BM, Buchbender C, Heusch P, Rabenalt R, Albers P, Antoch G, Müller HW, et al. Prospective comparison of whole-body MRI and Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging. PMID 30879122 DOI: 10.1007/S00259-019-04308-5 |
0.304 |
|
| 2019 |
Fossati N, Bleser ED, Karnes RJ, Heidenreich A, Stief C, Joniau S, Poppel HV, Osmonov D, Shariat S, Albers P, Tilki D, Graefen M, Gill IS, Gandaglia G, Mottrie A, et al. Mp22-06 Imaging Targeted Treatments Versus Extended Salvage Lymph Node Dissection For Patients With A Single Nodal Recurrence Of Prostate Cancer: A Comparative Analysis From A Large Multi-Institutional Series The Journal of Urology. 18. DOI: 10.1097/01.Ju.0000555590.28653.25 |
0.364 |
|
| 2019 |
Bravi C, Fossati N, Suardi N, Gandaglia G, Boeri L, Karnes RJ, Heidenreich A, Kretschmer A, Buchner A, Stief C, Battaglia A, Joniau S, Poppel HV, Kalz A, Osmonov D, ... ... Albers P, et al. Mp22-03 Long-Term Oncologic Outcomes Of Patients Treated With Salvage Lymph Node Dissection For Nodal Recurrence Of Prostate Cancer: Results From A Large, Multi-Institutional Series The Journal of Urology. 18. DOI: 10.1097/01.Ju.0000555587.43900.2B |
0.357 |
|
| 2019 |
Cortés CVB, Ullrich T, Quentin M, Mones F, Rabenalt R, Antoch G, Schimmöller L, Albers P, Arsov C. Multiparametric MRI can exclude prostate cancer progression in patients under active surveillance European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)30455-5 |
0.346 |
|
| 2018 |
Al-Monajjed R, Arsov C, Albers P. [Prostate cancer screening: controversies and suggested solutions]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. PMID 30397721 DOI: 10.1007/S00103-018-2840-X |
0.343 |
|
| 2018 |
Ahmadzadehfar H, Albers P, Bockisch A, Boegemann M, Böhme C, Burchert W, Dietlein M, Drzezga A, Fabry U, Feldmann G, Heidenreich A, Heinzel A, Herrmann K, Heyll A, Höhling C, et al. [Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein]. Der Urologe. Ausg. A. PMID 29671080 DOI: 10.1007/S00120-018-0642-2 |
0.339 |
|
| 2018 |
Cash H, Steiner U, Heidenreich A, Klotz T, Albers P, Melchior S, Martus P, Fuller F, Magheli A, Hinz S, Kempkensteffen C, Miller K. Intermittent docetaxel therapy versus continuous docetaxel therapy in patients with castration resistant prostate cancer (CRPC) - a phase III study (PRINCE). Bju International. PMID 29633515 DOI: 10.1111/Bju.14239 |
0.349 |
|
| 2018 |
Arsov C, Becker N, Herkommer K, Gschwend J, Imkamp F, Kuczyk M, Hadaschik B, Hohenfellner M, Siener R, Kristiansen G, Schimmöller L, Antoch G, Albers P. Mp57-04 The German Risk-Adapted Prostate Cancer Screening Trial (Probase) – First Results After Recruitment Of 30.000 Men The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1816 |
0.316 |
|
| 2018 |
Hiester A, Nini A, Niegisch G, Rabenalt R, Albers P. Mp52-08 Oncological Outcomes, Surgical Safety And Complications Of Patients Treated With Spot Specific Salvage Lymphnode Dissection (Slnd) For Positron-Emission Tomography (Pet) Positive Prostate Cancer (Pca) Relapse The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1659 |
0.328 |
|
| 2017 |
Gschwend JE, Albers P, Bögemann M, Goebell P, Heidenreich A, Klier J, König F, Machtens S, Pantel K, Thomas C. [Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data]. Der Urologe. Ausg. A. PMID 29071398 DOI: 10.1007/S00120-017-0533-Y |
0.349 |
|
| 2017 |
Ullrich T, Schimmöller L, Oymanns M, Blondin D, Dietzel F, Kirchner J, Arsov C, Rabenalt R, Albers P, Antoch G, Quentin M. Current Utilization and Acceptance of Multiparametric MRI in the Diagnosis of Prostate Cancer. A Regional Survey. Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin. PMID 28934811 DOI: 10.1055/S-0043-118128 |
0.34 |
|
| 2017 |
Ohlmann C-, Goebell PJ, Grimm M-, Klier J, König F, Machtens S, Schostak M, Schrader A-, Albers P. [Metastatic prostate cancer : Update: position paper for the use of chemotherapy]. Urologe A. 56: 1597-1602. PMID 28695241 DOI: 10.1007/S00120-017-0459-4 |
0.361 |
|
| 2017 |
Arsov C, Becker N, Herkommer K, Gschwend J, Imkamp F, Kuczyk M, Hadaschik B, Hohenfellner M, Siener R, Kristiansen G, Antoch G, Albers P. A positive digital rectal examination (DRE) does not predict prostate cancer in 45 yr old men - results from the German risk-adapted PCA Screening Trial (PROBASE) European Urology Supplements. 16. DOI: 10.1016/S1569-9056(17)30312-3 |
0.319 |
|
| 2017 |
Hiester A, Nini A, Niegisch G, Albers P, Mueller-Mattheis V, Rabenalt R. Pd24-03 Oncological Outcomes Of Patients Treated With Salvage Lymphnode Dissection (Slnd) For Positron-Emission Tomography (Pet) Positive Prostate Cancer (Pca) Relapse The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1080 |
0.311 |
|
| 2016 |
Miller K, Albers P, Eichenauer R, Geiges G, Grimm MO, König F, Mickisch G, Pfister D, Schwentner C, Suttmann H, Zastrow S. [Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring]. Der Urologe. Ausg. A. PMID 27411995 DOI: 10.1007/S00120-016-0176-4 |
0.324 |
|
| 2016 |
Kowalski C, Ferencz J, Albers P, Fichtner J, Wiegel T, Feick G, Wesselmann S. Quality assessment in prostate cancer centers certified by the German Cancer Society. World Journal of Urology. 34: 665-72. PMID 26391484 DOI: 10.1007/S00345-015-1688-Z |
0.311 |
|
| 2016 |
Herkommer K, Laenger NTS, Klorek T, Ankerst DP, Grill S, Schulwitz H, Albers P, Arsov C, Hadaschik BA, Hohenfellner M, Imkamp F, Kuczyk M, Gschwend JE. Pd15-04 The Association Between Family History And Prostate-Specific Antigen From A Large Group Of 45-Year Old Men Embarking On Prostate Cancer Screening: Results From The Probase Trial The Journal of Urology. 195. DOI: 10.1016/S1569-9056(16)60091-X |
0.33 |
|
| 2015 |
Fichtner J, Kowalski C, Wesselmann S, Albers P. [Indicator analysis of prostate cancer centers certified by the German Cancer Society 2015]. Der Urologe. Ausg. A. 54: 1530, 1532-6. PMID 26573670 DOI: 10.1007/S00120-015-3855-7 |
0.321 |
|
| 2015 |
Arsov C, Becker N, Rabenalt R, Hiester A, Quentin M, Dietzel F, Antoch G, Gabbert HE, Albers P, Schimmöller L. The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy. Journal of Cancer Research and Clinical Oncology. 141: 2061-8. PMID 26013424 DOI: 10.1007/s00432-015-1991-5 |
0.341 |
|
| 2015 |
Arsov C, Hiester A, Schimmöller L, Quentin M, Blondin D, Godehardt E, Antoch G, Albers P, Rabenalt R. 761 A prospective randomized study comparing MR-guided in-bore versus MRI/ultrasound fusionguided prostate biopsy in patients with prior tumor-negative TRUS biopsy European Urology Supplements. 14. DOI: 10.1016/S1569-9056(15)60752-7 |
0.34 |
|
| 2014 |
Quentin M, Blondin D, Arsov C, Schimmöller L, Hiester A, Godehardt E, Albers P, Antoch G, Rabenalt R. Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen. The Journal of Urology. 192: 1374-9. PMID 24866597 DOI: 10.1016/J.Juro.2014.05.090 |
0.313 |
|
| 2014 |
Hiester A, Arsov C, Quentin M, Schimmöller L, Blondin D, Antoch G, Albers P, Rabenalt R. 1057 Correlation of the PI-RADS score and the Gleason grade in prostate cancer lesions after targeted in bore MR-biopsy European Urology Supplements. 13. DOI: 10.1016/S1569-9056(14)61039-3 |
0.316 |
|
| 2014 |
Hiester A, Arsov C, Quentin M, Schimmöller L, Godehardt E, Blondin D, Antoch G, Albers P, Rabenalt R. 948 Comparison of targeted in-bore MRI–guided biopsy and conventional transrectal ultrasound (TRUS) – guided biopsy in biopsy-naïve patients with elevated prostate specific antigen (PSA) level European Urology Supplements. 13. DOI: 10.1016/S1569-9056(14)60932-5 |
0.311 |
|
| 2014 |
Müller-Mattheis V, Hautzel H, Fahlbusch M, Albers P. 729 11C-acetate PET/CT imaging for detection of recurrent disease following radical prostatectomy or radiotherapy in patients with prostate carcinoma European Urology Supplements. 13. DOI: 10.1016/S1569-9056(14)60718-1 |
0.309 |
|
| 2013 |
Wiegel T, Albers P, Bussar-Maatz R, Gottberg A, Härter M, Kieser M, Kristiansen G, Nettekoven G, Martus P, Schmidberger H, Wellek S, Stöckle M. [PREFERE - the German prostatic cancer study: questions and claims surrounding study initiation in January 2013]. Der Urologe. Ausg. A. 52: 576-9. PMID 23571802 DOI: 10.1007/S00120-013-3186-5 |
0.349 |
|
| 2013 |
Barski D, Richter M, Winter C, Arsov C, de Geeter P, Rabenalt R, Albers P. Holmium laser ablation of the prostate (HoLAP): intermediate-term results of 144 patients. World Journal of Urology. 31: 1253-9. PMID 22782618 DOI: 10.1007/S00345-012-0901-6 |
0.307 |
|
| 2012 |
Bavbek SE, Malik Z, Di Lorenzo G, Scholz HJ, van Oort IM, Ng S, Ozguroglu M, Gerritsen WR, Mueller S, Marttila T, Anton-Aparicio LM, Albers P, Gschwend J, Bensfia S, Ecstein-Fraïssé EB, et al. A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 172. PMID 27968103 DOI: 10.1200/Jco.2012.30.15_Suppl.E15112 |
0.308 |
|
| 2012 |
Quentin M, Blondin D, Klasen J, Schek J, Buchbender C, Miese FR, Antoch G, Barski D, Albers P, Arsov C. Evaluation of a structured report of functional prostate magnetic resonance imaging in patients with suspicion for prostate cancer or under active surveillance. Urologia Internationalis. 89: 25-9. PMID 22677880 DOI: 10.1159/000338808 |
0.337 |
|
| 2012 |
Arsov C, Blondin D, Rabenalt R, Antoch G, Albers P, Quentin M. [Standardised scoring of a multi-parametric 3-T MRI for a targeted MRI-guided prostate biopsy]. Der Urologe. Ausg. A. 51: 848-56. PMID 22476739 DOI: 10.1007/S00120-012-2825-6 |
0.304 |
|
| 2012 |
Heidenreich A, Albers P, Bokemeyer C, Goebell P, Gschwend J, Miller K, Müller S, Otremba B, Reuter C, Trojan L, Volkmer B, Wirth M. 128 Cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen: Interim analysis on treatment associated side effects resulting from a compassionate-use programme (CUP) European Urology Supplements. 11. DOI: 10.1016/S1569-9056(12)60127-4 |
0.351 |
|
| 2011 |
Niegisch G, Fimmers R, Siener R, Park S, Albers P. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel: German Association of Urological Oncology (AUO) trial AB 20/99. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4586. PMID 28023310 DOI: 10.1200/Jco.2011.29.15_Suppl.4586 |
0.31 |
|
| 2011 |
Gschwend JE, Albers P, Schrader M. Prostatakarzinomzentren und Hodentumorzweitmeinungszentren Urologe A. 50: 921-927. PMID 21785887 DOI: 10.1007/S00120-011-2540-8 |
0.337 |
|
| 2011 |
Pfister DJ, Busch J, Winter C, Schrader M, Dieckmann K, Schmelz HU, Albers P, Heidenreich A. Comparing the perioperative management of postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in patients with pure seminomatous and nonseminomatous germ cell tumors (NSGCT). Journal of Clinical Oncology. 29: 230-230. DOI: 10.1200/Jco.2011.29.7_Suppl.230 |
0.308 |
|
| 2011 |
Pfister DJ, Busch J, Winter C, Schmelz HU, Dieckmann K, Albers P, Schrader M, Heidenreich A. Pathohistologic findings in patients with nonseminomatous germ cell tumors (NSGCT) who undergo postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for small tumors. Journal of Clinical Oncology. 29: 224-224. DOI: 10.1200/Jco.2011.29.7_Suppl.224 |
0.338 |
|
| 2011 |
Winter C, Pfister DJKP, Bingoel C, Busch J, Ranft U, Schrader M, Dieckmann KP, Heidenreich A, Albers P. Predictive factors for additional vascular procedures in patients with germ cell tumors (GCT) and residual tumor resection (RTR): A multicenter analysis of the German Testicular Cancer Study Groups (GTCSG). Journal of Clinical Oncology. 29. DOI: 10.1200/Jco.2011.29.15_Suppl.E15050 |
0.305 |
|
| 2011 |
Müller-Mattheis V, Fahlbusch M, Hautzel H, Albers P. 969 11C-Acetate Pet/Ct Imaging Of Prostate Cancer: Detection Of Recurrent Disease In Patients With Psa Relapse Following Radical Prostatectomy Or Radiotherapy European Urology Supplements. 10: 302. DOI: 10.1016/S1569-9056(11)60951-2 |
0.332 |
|
| 2011 |
Heidenreich A, Scholz HJ, Oort Iv, Bavbek S, Mueller S, Ozguroglu M, Albers P, Gschwend J, Ecstein-Fraïssé E. 7044 POSTER Cabazitaxel Plus Prednisone for Patients With Metastatic Castration-resistant Prostate Cancer Previously Treated With a Docetaxel-containing Regimen – Interim Analysis Results From an Ongoing Compassionate-use Programme European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)71995-5 |
0.353 |
|
| 2011 |
Winter C, Bingöl C, Albers P. Postchemotherapy Retroperitoneal Residual Tumor Resection for Minimal Residual Disease European Urology Supplements. 10. DOI: 10.1016/J.Eursup.2011.03.013 |
0.311 |
|
| 2010 |
Heidenreich A, Albers P, Classen J, Graefen M, Gschwend J, Kotzerke J, Krege S, Lehmann J, Rohde D, Schmidberger H, Uder M, Zeeb H. Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. Urologia Internationalis. 85: 1-10. PMID 20693823 DOI: 10.1159/000318985 |
0.334 |
|
| 2010 |
Albers P, Fahlbusch M, Hautzel H, Mueller-Mattheis V. 11C-acetate PET/CT imaging of prostate cancer: Detection of recurrent disease in patients with PSA relapse following radical prostatectomy. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E15080 |
0.352 |
|
| 2010 |
Heidenreich A, Winter C, Pfister D, Angerer-Shpilenya M, Brehmer B, Albers P. 638 Complications Of Post-Chemotherapy Retroperitoneal Lymph Node Dissection (Pcrplnd) In Advanced Nonseminomatous Germ Cell Tumors – First Results Of The German Testicular Cancer Study Group The Journal of Urology. 183: 237. DOI: 10.1016/J.Juro.2010.02.1012 |
0.311 |
|
| 2009 |
Hartmann M, Siener R, Krege S, Schmelz H, Dieckmann K-, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann K-, Fimmers R, Weißbach L, Loy V, Wittekind C, ... Albers P, et al. Ergebnisse der randomisierten Phase-III-Studie der „German Testicular Cancer Study Group“ Urologe A. 48: 523-528. PMID 19183929 DOI: 10.1007/S00120-008-1927-7 |
0.323 |
|
| 2009 |
Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, et al. [Complete resection of urothelial cancer metastases with curative intent]. Der Urologe. Ausg. A. 48: 143-50. PMID 19142626 DOI: 10.1007/S00120-008-1901-4 |
0.343 |
|
| 2009 |
Albers P, Bingol C, Witthuhn R, Geeter Pd. Complications of postchemotherapy residual tumor resection in patients with germ cell cancer Journal of Clinical Oncology. 27. DOI: 10.1200/Jco.2009.27.15_Suppl.E16077 |
0.324 |
|
| 2008 |
Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2966-72. PMID 18458040 DOI: 10.1200/Jco.2007.12.0899 |
0.325 |
|
| 2008 |
Czeloth K, Geeter PD, Loehmer H, Jost N, Albers P. Radical cystectomy and continent diversion in patients with non organ-confined bladder cancer Journal of Clinical Oncology. 26: 16072-16072. DOI: 10.1200/Jco.2008.26.15_Suppl.16072 |
0.312 |
|
| 2008 |
Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weißbach L, Loy V, Wittekind C, et al. Randomised Phase Iii Trial Comparing Retroperitoneal Lymph Node Dissection (Rplnd) With One Course Of Bleomycin, Etoposide, Cisplatin (Bep) Chemotherapy In Patients With Stage I Non-Seminomatous Germ Cell Tumour Patients (Nsgct) – Updated Results Of Auo Trial 01/94 European Urology Supplements. 7: 84. DOI: 10.1016/S1569-9056(08)60057-3 |
0.309 |
|
| 2007 |
Albers P, Schäfers S, Löhmer H, Geeter Pd. Seminal vesicle-sparing perineal radical prostatectomy improves early functional results in patients with low-risk prostate cancer. Bjui. 100: 1050-1054. PMID 17760889 DOI: 10.1111/J.1464-410X.2007.07123.X |
0.356 |
|
| 2007 |
Albers P. Management of Stage I Testis Cancer{A figure is presented} European Urology. 51: 34-44. PMID 16996677 DOI: 10.1016/J.Eururo.2006.08.022 |
0.346 |
|
| 2007 |
Albers P. Do We Need the Final Results of the ERSPC Trial? European Urology. 51: 291-292. PMID 16949198 DOI: 10.1016/J.Eururo.2006.07.044 |
0.357 |
|
| 2006 |
Krege S, Boergermann C, Baschek R, Hinke A, Pottek T, Kliesch S, Dieckmann K-, Albers P, Knutzen B, Weinknecht S, Schmoll H-, Beyer J, Ruebben H. Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG) Annals of Oncology. 17: 276-280. PMID 16254023 DOI: 10.1093/Annonc/Mdj039 |
0.308 |
|
| 2006 |
Albers P, Siener R, Krege S, Schmelz H, Dieckmann K, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Fimmers R, Hartmann M. One course of adjuvant PEB chemotherapy versus retroperitoneal lymph node dissection in patients with stage I non-seminomatous germ-cell tumors (NSGCT): Results of the German Prospective Multicenter Trial (Association of Urological Oncology [AUO]/German Testicular Cancer Study Group [GTCSG] Trial 01–94) Journal of Clinical Oncology. 24: 4512-4512. DOI: 10.1200/Jco.2006.24.18_Suppl.4512 |
0.328 |
|
| 2006 |
Schostak M, Schrader M, Albers P, Beer M, Althaus P, Diederichs W, Siegsmund M, Fabricius G, Miller K. Visible Quality - Benchmarking In Prostate Cancer Therapy European Urology Supplements. 5: 319. DOI: 10.1016/S1569-9056(06)61191-3 |
0.317 |
|
| 2005 |
Lehmann J, Retz M, Wiemers C, Beck J, Thüroff J, Weining C, Albers P, Frohneberg D, Becker T, Funke P, Walz P, Langbein S, Reiher F, Schiller M, Miller K, et al. Adjuvant Cisplatin Plus Methotrexate Versus Methotrexate, Vinblastine, Epirubicin, and Cisplatin in Locally Advanced Bladder Cancer: Results of a Randomized, Multicenter, Phase III Trial (AUO-AB 05/95) Journal of Clinical Oncology. 23: 4963-4974. PMID 15939920 DOI: 10.1200/Jco.2005.11.094 |
0.339 |
|
| 2005 |
Ko Y, Hahn T, Lu H, Ma ZL, Chen J, Rothe M, Florin A, Fronhoffs S, Albers P, Sachinidis A, Vetter H, Kaminski A, Behrens P, Wellmann A, Wernert N. A novel component of the ubiquitin pathway, ubiquitin carboxyl extension protein 1 is overexpressed in prostate cancer. International Journal of Molecular Medicine. 15: 183-196. DOI: 10.3892/Ijmm.15.2.183 |
0.315 |
|
| 2005 |
Heidenreich A, Albers P, Weiβbach L. Organ preserving surgery in testicular cancer - long-term results of the German Testicular Cancer Study Group Journal of Clinical Oncology. 23: 4523-4523. DOI: 10.1200/Jco.2005.23.16_Suppl.4523 |
0.306 |
|
| 2004 |
Bastian PJ, Skowasch D, Bauriedel G, Behrens P, Müller SC, Albers P. Primary extragonadal germ cell tumor of the prostate in a young man International Journal of Urology. 11: 671-673. PMID 15285762 DOI: 10.1111/J.1442-2042.2004.00861.X |
0.34 |
|
| 2004 |
Lehmann J, Retz M, Thüroff JW, Weining C, Albers P, Becker T, Wellek S, Stöckle M. 312: Survival After Disease Progression of Patients with Locally Advanced Bladder Cancer Previously Treated with Radical Cystectomy and Adjuvant Chemotherapy – Experience from a Large Multicenter Trial The Journal of Urology. 171: 82-82. DOI: 10.1016/S0022-5347(18)37574-8 |
0.327 |
|
| 2003 |
Lehmann J, Retz M, Steiner G, Albers P, Jaeger E, Knuth A, Lippert C, Koser M, Stockamp K, Otto C, Melchior H, Fassmann C, Potratz C, Loch T, Derigs HG, et al. [Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany]. Der Urologe. Ausg. A. 42: 1074-86. PMID 14513232 DOI: 10.1007/S00120-003-0317-4 |
0.327 |
|
| 2003 |
Heidenreich A, Albers P, Hartmann M, Kliesch S, Köhrmann K, Krege S, Lossin P, Weissbach L. Complications of Primary Nerve Sparing Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Experience of the German Testicular Cancer Study Group The Journal of Urology. 169: 1710-1714. PMID 12686815 DOI: 10.1097/01.Ju.0000060960.18092.54 |
0.305 |
|
| Show low-probability matches. |